In prostate cancer, overexpression of HECTD4 has been reported to result in a simultaneous decrease in both androgen receptor (AR) and MYC proteins, while knockdown of HECTD4 results in an increase in both AR and MYC proteins. This evidence concerns the gene HECTD4 and Familial prostate cancer.